Submammary placement of implantable cardioverter defibrillators: a Singapore plastic surgeon experience

Autor: JC Goh, E Boey, P Kojodjojo, N Vigneswaran

Publikováno v: Singapore Med J

The use of implantable cardioverter defibrillators (ICDs) in young women has been increasing in recent years owing to greater awareness about inherited cardiac conditions that increase the risk of sudden death. Traditional placement of ICDs in the in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c37c9474663e41c36133ae395dc1bc7
https://europepmc.org/articles/PMC9251215/

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

Autor: Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Bex A; Netherlands Cancer Institute, Amsterdam, the Netherlands.; University College London, London, United Kingdom., Russo P; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY., Tomita Y; Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Cutuli HJ; Hospital Sirio Libanés, Buenos Aires, Argentina., Rojas C; Bradford Hill, Santiago, Chile., Gross-Goupil M; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France., Schinzari G; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Melichar B; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic., Barthélémy P; Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Ruiz Garcia A; Hospital 1ro de Octubre, Mexico City, Mexico., Sosman J; Northwestern University Medical Center, Chicago, IL., Grimm MO; Jena University Hospital, Jena, Germany., Goh JC; ICON Research, South Brisbane, QLD, Australia., Suarez C; Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Kollmannsberger CK; BC Cancer, Vancouver, BC, Canada., Nair SG; Lehigh Valley Health Network, Allentown, PA., Shuch BM; University of California Los Angeles, Los Angeles, CA., Huang J; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China., Simsek B; Bristol Myers Squibb, Princeton, NJ., Spiridigliozzi J; Bristol Myers Squibb, Princeton, NJ., Lee CW; Bristol Myers Squibb, Princeton, NJ., van Kooten Losio M; Bristol Myers Squibb, Princeton, NJ., Grünwald V; University Hospital Essen, Essen, Germany.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 20, pp. JCO2400773. Date of Electronic Publication: 2024 Sep 20.

[ ¹⁷⁷ Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.

Autor: Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia. Electronic address: louise.emmett@svha.org.au., Subramaniam S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, NSW, Australia., Crumbaker M; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia; Macquarie University Hospital, Sydney, NSW, Australia., Nguyen A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia., Joshua AM; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia., Weickhardt A; Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia., Lee ST; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; Department of Medicine and Department of Surgery, University of Melbourne, Melbourne, VIC, Australia., Ng S; Department of Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia; Department of Oncology, University of Western Australia, Perth, WA, Australia., Francis RJ; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia., Goh JC; Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; Queensland University of Technology, Brisbane, QLD, Australia., Pattison DA; Department of Nuclear Medicine and Specialised PET Services, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland, Brisbane, QLD, Australia., Tan TH; Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia., Kirkwood ID; Nuclear Medicine, PET and Bone Densitometry, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia., Gedye C; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia., Rutherford NK; Department of Nuclear Medicine, Hunter New England Health, Newcastle, NSW, Australia., Sandhu S; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Kumar AR; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Pook D; Department of Oncology, Monash Health, Melbourne, VIC, Australia., Ramdave S; Monash Health Imaging, Monash Health, Melbourne, VIC, Australia., Nadebaum DP; Department of Oncology, Alfred Health, Melbourne, VIC, Australia., Voskoboynik M; Department of Oncology, Alfred Health, Melbourne, VIC, Australia; Central Clinical School, Monash University, Melbourne, VIC, Australia., Redfern AD; Medical School, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA, Australia., Macdonald W; Medical School, University of Western Australia, Perth, WA, Australia; Department of Nuclear Medicine, Fiona Stanley Hospital, Perth, WA, Australia., Krieger L; Genesis Care North Shore, Sydney, NSW, Australia., Schembri G; Nuclear Medicine, Royal North Shore Hospital, Sydney, NSW, Australia., Chua W; Department of Medical Oncology, Liverpool Hospital, Sydney, NSW, Australia; Western Sydney University, Sydney, NSW, Australia., Lin P; South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia; Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, NSW, Australia., Horvath L; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Bastick P; Department of Medical Oncology, St George Hospital, Sydney, NSW, Australia., Butler P; Department of Nuclear Medicine, St George Hospital, Sydney, NSW, Australia., Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Macquarie University Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Yip S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Thomas H; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Langford A; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Hofman MS; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., McJannett M; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, NSW, Australia., Martin AJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Davis ID; Monash University Eastern Health Clinical School, Melbourne, VIC, Australia; Eastern Health, Melbourne, VIC, Australia.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 May; Vol. 25 (5), pp. 563-571. Date of Electronic Publication: 2024 Apr 12.

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.

Autor: Grünwald V; Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany., Powles T; Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan., Kopyltsov E; State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea., Porta C; Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy., Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Hutson TE; Medical Oncology, Texas Oncology, Dallas, TX, United States., Méndez-Vidal MJ; Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain., Hong SH; Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea., Winquist E; Department of Oncology, University of Western Ontario, London, ON, Canada., Goh JC; ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia., Maroto P; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Buchler T; Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia., Takagi T; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan., Burgents JE; Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States., Perini R; Clinical Research, Merck & Co., Inc., Rahway, NJ, United States., He C; Biostatistics, Eisai Inc., Nutley, NJ, United States., Okpara CE; Clinical Research, Eisai Ltd., Hatfield, United Kingdom., McKenzie J; Clinical Research, Eisai Inc., Nutley, NJ, United States., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2024 Mar 01; Vol. 13, pp. 1343027. Date of Electronic Publication: 2024 Mar 01 (Print Publication: 2023).

Overall survival with [ ¹⁷⁷ Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.

Autor: Hofman MS; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia. Electronic address: michael.hofman@petermac.org., Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia., Sandhu S; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia., Iravani A; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Buteau JP; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia., Joshua AM; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia., Goh JC; Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; Queensland University of Technology, Brisbane, QLD, Australia., Pattison DA; Department of Nuclear Medicine and Specialised PET Services, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland, Brisbane, QLD, Australia., Tan TH; Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia., Kirkwood ID; Department of Nuclear Medicine and PET, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia., Ng S; Department of Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia., Francis RJ; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia., Gedye C; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia., Rutherford NK; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia; Department of Nuclear Medicine, Hunter New England Health, New Lambton, NSW, Australia., Weickhardt A; Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia., Scott AM; Department of Medicine, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia., Lee ST; Department of Medicine, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia., Kwan EM; Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia., Azad AA; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia., Ramdave S; Monash Health Imaging, Monash Health, Melbourne, VIC, Australia., Redfern AD; Medical School, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA, Australia., Macdonald W; Medical School, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA, Australia; Department of Nuclear Medicine, Fiona Stanley Hospital, Perth, WA, Australia., Guminski A; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia., Hsiao E; Department of Nuclear Medicine and PET, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia., Chua W; Department of Medical Oncology, Liverpool Hospital, Sydney, NSW, Australia., Lin P; Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia; Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, NSW, Australia., Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Macquarie University Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Williams SG; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia., Martin AJ; Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Davis ID; Monash University Eastern Health Clinical School, Melbourne, VIC, Australia; Eastern Health Department of Cancer Services, Eastern Health, Melbourne, VIC, Australia.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Jan; Vol. 25 (1), pp. 99-107. Date of Electronic Publication: 2023 Nov 30.